Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

Different options are available as second-line treatment of metastatic castrate-resistant prostate cancer: cabazitaxel, abiraterone, and enzalutamide. Phase III studies evaluating cabazitaxel and the two hormonal agents have been shown to significantly prolong overall survival compared to mitoxantro...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Irelli, A., Bruera, G., Cannita, K., Palluzzi, E., Gravina, G. L., Festuccia, C., Ficorella, C., Ricevuto, E.
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi Publishing Corporation 2014
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058260/
https://ncbi.nlm.nih.gov/pubmed/24971356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/909623
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky